- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Juliette Petit: How Nurses Can Prevent Nocebo Effect in Biosimilar Switching
Juliette Petit, MD, a French rheumatologist, talks about her recent study showing that nurses can help curb patient fears and prevent a possible nocebo effect when switching them to a biosimilar.
If you are aware of the placebo effect, you may have heard of its opposite relative, the nocebo effect, where instead of positive thinking leading to an improvement in health, patient fears about drug quality may result in little or no effect from therapy. The nocebo effect is a common concern in the biosimilar space, where patients often doubt whether biosimilars are clinically similar to reference products.
A recent study on the nocebo effect in biosimilar use demonstrated that nurses may be best able to boost patient confidence in biosimilars and improve retention rates. The authors noted that because nurses are usually the first point of contact for patients in the health care system, they can be effective advocates at facilitating switching and biosimilar acceptance.
We sat down with Juliette Petit, MD, a rheumatologist at Saint-Antoine Hospital at Sorbonne University in Paris, France, and one of the study’s co-authors to discuss some of the major points in her study what it could mean for the future of biosimilar uptake.
Learn more about Dr Petit’s study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
